Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4101 Pulmonary neuroendocrine tumors – Symptomatology, tumor characteristics, treatment strategies, and long-term outcomes in 37 Patients

Introduction: Pulmonary Neuroendocrine Tumors (NET) constitute a complex group of diseases with varied clinical manifestations and no definitive diagnostic and treatment guidelines.

Conference:

Presenting Author: Krishna B

Authors: Jain D, Eshpuniyani P, Deshpande R, Sharma S, Krishna B,

Keywords: epidemiology, pulmonary NET, lobectomy, prognosis,

#3744 Germline whole-exome sequencing of patients with neuroendocrine neoplasms reveals pathogenic or likely pathogenic variants in a large subset of patients

Introduction: The germline predisposition to neuroendocrine neoplasms (NEN) is not-well understood beyond genetic syndromes associated with MEN1 loss.

Conference:

Presenting Author: Sukrithan V

Authors: Sukrithan V, Boateng I, Jain P, Liyanarachchi S, Buss J,

Keywords: whole exome sequencing, germline, population, mutyh, pkd1, atp4a, pah,

#3726 Inflammation based index and tumor heterogeneity on pretherapeutic 68Ga DOTATOC PET/CT predict outcome in midgut neuroendocrine tumor patients treated with 177Lu-oxodotreotide

Introduction: Peptide receptor radionuclide therapy with 177Lu oxodotreotide (LuPRRT) is a standard treatment for the management of patients with inoperable metastatic well-differentiated neuroendocrine tumors of the midgut (iNET). As LuPRRT becomes widely used for a heterogeneous population of NET patients, practical predictive biomarkers are needed. Inflammation based index (IBI) derived from serum C reactive protein and albumin is associated with progression free survival (PFS) and overall survival (OS) in patients with PRRT for NETs. Ga-68 DOTATOC PET/CT (DOTAPET) assessment of lesion heterogeneity was predictive for response to PRRT.

Conference:

Presenting Author: Vija L

Authors: Vija L, Dierickx L, Kanoun S, Texier J, Terroir M,

Keywords: LuPRRT, GaDOTA PET/CT, neuroendocrine tumor, outcome,